Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ODM-208 |
| Synonyms | |
| Therapy Description |
ODM-208 is a selective inhibitor of CYP11A1, which potentially inhibits steroid biosynthesis and tumor growth (PMID: 36129801). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ODM-208 | ODM208|ODM 208|MK-5684|MK5684|MK 5684|Opevesostat | ODM-208 is a selective inhibitor of CYP11A1, which potentially inhibits steroid biosynthesis and tumor growth (PMID: 36129801). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03436485 | Phase Ib/II | ODM-208 | Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES) | Active, not recruiting | USA | GBR | FRA | FIN | 0 |
| NCT06353386 | Phase Ib/II | ODM-208 ODM-208 + Olaparib Docetaxel + ODM-208 Cabazitaxel + ODM-208 | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | Recruiting | USA | TUR | POL | NZL | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUS | 5 |